New drugs drive optimism at AstraZeneca

New drugs drive optimism at AstraZeneca

Reported half-year numbers from pharma giant AstraZeneca (AZN) were poor. Drug sales fell 2 per cent to $10bn (£7.6bn) at constant currencies, while rising costs sent core operating profits down 34 per cent to $2.2bn.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now